EXAS

66.18

1.55% -1.04

Handel nachbörslich: 66.25 0.07 +0.11%

Exact Sciences Corp (EXAS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$67.22

Offen:

$66.53

24-Stunden-Volumen:

3.00M

Relative Volume:

0.99

Marktkapitalisierung:

$12.53B

Einnahmen:

$2.83B

Nettoeinkommen (Verlust:

$-1.02B

KGV:

-12.01

EPS:

-5.51

Netto-Cashflow:

$194.14M

1W Leistung:

+2.30%

1M Leistung:

+14.60%

6M Leistung:

+24.21%

1J Leistung:

+24.33%

1-Tages-Spanne:

$64.92

$67.27

1-Wochen-Bereich:

$64.02

$72.81

52-Wochen-Spanne:

$38.81

$72.81

Exact Sciences Corp Stock (EXAS) Company Profile

Firmenname

Exact Sciences Corp

Sektor

Healthcare (1134)

Branche

Diagnostics & Research (53)

Telefon

608-284-5700

Adresse

5505 ENDEAVOR LANE, MADISON, WI

Mitarbeiter

7,000

Twitter

@exactsciences

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

EXAS's Discussions on Twitter

Vergleichen Sie EXAS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EXAS Exact Sciences Corp	66.18	12.74B	2.83B	-1.02B	194.14M	-5.51
TMO Thermo Fisher Scientific Inc	572.41	212.64B	43.74B	6.58B	6.11B	17.31
DHR Danaher Corp	209.94	148.81B	24.27B	3.50B	5.02B	4.8589
IDXX Idexx Laboratories Inc	708.45	56.99B	4.17B	1.03B	940.22M	12.61
A Agilent Technologies Inc	146.74	41.81B	6.79B	1.22B	1.09B	4.2644
IQV Iqvia Holdings Inc	210.46	35.91B	15.90B	1.28B	2.21B	7.2842

Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-10	Eingeleitet	Mizuho	Outperform
2025-03-13	Eingeleitet	RBC Capital Mkts	Sector Perform
2025-01-23	Eingeleitet	Barclays	Overweight
2024-08-28	Eingeleitet	Wells Fargo	Overweight
2024-06-27	Eingeleitet	Scotiabank	Sector Outperform
2024-06-03	Fortgesetzt	Jefferies	Buy
2024-01-02	Hochstufung	The Benchmark Company	Hold → Buy
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-10-10	Hochstufung	Piper Sandler	Neutral → Overweight
2023-09-28	Eingeleitet	Bernstein	Outperform
2023-08-02	Herabstufung	The Benchmark Company	Buy → Hold
2023-05-10	Hochstufung	Craig Hallum	Hold → Buy
2023-05-05	Eingeleitet	UBS	Neutral
2023-03-09	Hochstufung	Citigroup	Neutral → Buy
2023-02-10	Herabstufung	Credit Suisse	Outperform → Neutral
2023-01-18	Herabstufung	Raymond James	Outperform → Mkt Perform
2022-10-19	Herabstufung	Craig Hallum	Buy → Hold
2022-08-25	Eingeleitet	Credit Suisse	Outperform
2022-06-03	Eingeleitet	Piper Sandler	Neutral
2021-11-03	Herabstufung	Raymond James	Strong Buy → Outperform
2021-07-29	Bestätigt	BTIG Research	Buy
2021-07-29	Bestätigt	Canaccord Genuity	Buy
2021-07-29	Bestätigt	Oppenheimer	Outperform
2021-07-29	Bestätigt	Stifel	Buy
2021-06-15	Eingeleitet	Raymond James	Strong Buy
2021-06-03	Eingeleitet	Goldman	Buy
2021-05-25	Eingeleitet	Wells Fargo	Equal Weight
2021-01-28	Eingeleitet	Truist	Buy
2020-10-29	Herabstufung	UBS	Buy → Neutral
2020-10-28	Herabstufung	Citigroup	Buy → Neutral
2020-10-08	Fortgesetzt	BTIG Research	Buy
2020-04-02	Eingeleitet	Evercore ISI	Outperform
2020-01-10	Fortgesetzt	BTIG Research	Buy
2020-01-07	Eingeleitet	Citigroup	Buy
2019-12-13	Eingeleitet	Dougherty & Company	Buy
2019-11-15	Eingeleitet	Stifel	Buy
2019-10-17	Bestätigt	BofA/Merrill	Buy
2019-10-01	Fortgesetzt	Craig Hallum	Buy
2019-09-26	Eingeleitet	Oppenheimer	Outperform
2019-02-26	Hochstufung	Goldman	Neutral → Buy
2018-10-09	Eingeleitet	UBS	Buy
2018-09-05	Fortgesetzt	The Benchmark Company	Hold
2018-08-13	Bestätigt	Canaccord Genuity	Buy
2018-04-03	Hochstufung	BTIG Research	Neutral → Buy
2018-01-29	Eingeleitet	Goldman	Neutral
2018-01-08	Bestätigt	The Benchmark Company	Buy
2017-11-13	Herabstufung	Robert W. Baird	Outperform → Neutral
2017-11-01	Herabstufung	BTIG Research	Buy → Neutral

Alle ansehen

Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten

Nov 07, 2025

Exact Sciences announces results from ALTUS study - TipRanks

Nov 07, 2025

Exact Sciences (EXAS) Is Up 6.3% After Oncoguard Liver Test Outperforms Ultrasound in ALTUS Study - Yahoo Finance

Nov 07, 2025

Exact Sciences' Blood Test Detects Liver Cancer Far Earlier Than Standard Ultrasound - Nasdaq

Nov 07, 2025

Exact Sciences Says Blood Test Beats Ultrasound for Quicker Liver Cancer Detection in Study - MarketScreener

Nov 07, 2025

EXAS Unveils Promising Results from ALTUS Study with Oncoguard L - GuruFocus

Nov 07, 2025

Exact Sciences’ liver cancer blood test shows superior early detection - Investing.com

Nov 07, 2025

Exact Sciences blood test shows improved liver cancer detection - StreetInsider

Nov 07, 2025

Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test - Business Wire

Nov 07, 2025

Nov 06, 2025

Herriott James, Exact Sciences Corp SVP, sells $105k in stock - Investing.com Canada

Nov 06, 2025

Baranick, Exact Sciences EVP, sells $200k in EXAS stock - Investing.com

Nov 06, 2025

Exact Sciences (EXAS) Gets a Hold from UBS - The Globe and Mail

Nov 06, 2025

Why Exact Sciences Corporation stock remains on buy listsWeekly Trend Recap & Weekly Consistent Profit Watchlists - fcp.pa.gov.br

Nov 06, 2025

How Exact Sciences Corporation stock performs in weak economy2025 Bull vs Bear & Daily Volume Surge Signals - newser.com

Nov 06, 2025

Why Exact Sciences Corporation stock could see breakout soonJuly 2025 Sector Moves & AI Driven Price Forecasts - fcp.pa.gov.br

Nov 06, 2025

Can Exact Sciences Corporation (EXK) stock stage a strong rebound this quarter - newser.com

Nov 06, 2025

Exact Sciences Corporation stock chart pattern explainedTrade Performance Summary & AI Optimized Trade Strategies - newser.com

Nov 06, 2025

Leading vs lagging indicators on Exact Sciences Corporation performance2025 Analyst Calls & Risk Managed Investment Signals - newser.com

Nov 06, 2025

Nov 05, 2025

EXAS Stock Quote Price and Forecast - CNN

Nov 05, 2025

Key facts: Exact Sciences raises 2025 revenue forecast to $3.23B; Wells Fargo boosts price target to $85 - TradingView

Nov 05, 2025

Exact Sciences (NASDAQ:EXAS) Trading 8.1% Higher After Better-Than-Expected Earnings - MarketBeat

Nov 05, 2025

EXAS: Wells Fargo Raises Price Target to $85.00, Maintains Overw - GuruFocus

Nov 05, 2025

Is Exact Sciences Corporation stock a buy for dividend growthJuly 2025 Outlook & Technical Pattern Based Buy Signals - newser.com

Nov 05, 2025

Exact Sciences Corporation (NASDAQ:EXAS) Q3 2025 Earnings Call Transcript - Insider Monkey

Nov 05, 2025

Exact Sciences to Participate in November 2025 Investor Conference - BioSpace

Nov 05, 2025

Exact Sciences Corp Faces Regulatory Risks Amid Potential Government Disruptions - TipRanks

Nov 05, 2025

Nov 04, 2025

Key facts: Exact Sciences Q3 Revenue Hits $850.7M; Cancerguard Launched; Analysts Raise Price Targets - TradingView

Nov 04, 2025

EXAS: TD Cowen Raises Price Target to $90 on Buy Rating | EXAS S - GuruFocus

Nov 04, 2025

Exact Sciences (EXAS) Receives Updated Analyst Rating from Baird - GuruFocus

Nov 04, 2025

EXAS: Benchmark Raises Price Target to $75 in Latest Analyst Rev - GuruFocus

Nov 04, 2025

EXAS: Guggenheim Raises Price Target to $75 While Maintaining Bu - GuruFocus

Nov 04, 2025

Stifel raises Exact Sciences stock price target to $80 on strong Cologuard growth - Investing.com Canada

Nov 04, 2025

EXAS: Barclays Raises Price Target to $77, Maintains Overweight Rating | EXAS Stock News - GuruFocus

Nov 04, 2025

These Analysts Raise Their Forecasts On Exact Sciences Following Better-Than-Expected Q3 Results - Benzinga

Nov 04, 2025

Madison-based Exact Sciences reports Q3 results topping analysts’ expectations - Wisconsin State Journal

Nov 04, 2025

EXAS Q3 Deep Dive: Cologuard Plus, Care Gap Programs, and New Test Launches Drive Growth - Yahoo! Finance Canada

Nov 04, 2025

EXAS: Stifel Raises Target Price to $80, Maintains Buy Rating | - GuruFocus

Nov 04, 2025

BTIG Raises Price Target for Exact Sciences (EXAS) to $85 | EXAS Stock News - GuruFocus

Nov 04, 2025

Exact Sciences stock price target raised to $85 from $75 at BTIG - Investing.com

Nov 04, 2025

Exact Sciences to Participate in November Investor Conference - Bluefield Daily Telegraph

Nov 04, 2025

Exact Sciences: Q3 Earnings Snapshot - theheraldreview.com

Nov 04, 2025

How Intuitive Surgical Stock Gained 19.5% Last Month - AOL.com

Nov 04, 2025

Canaccord Genuity raises Exact Sciences stock price target to $85 on strong growth - Investing.com

Nov 04, 2025